Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4

Rakesh Heer; Wei Shen Tan; Paul Gravestock; Thenmalar Vadiveloo; Rebecca Lewis; Steven Penegar; Luke Vale; Graeme MacLennan; Emma Hall; PHOTO Trial Team

doi:10.1016/j.eururo.2023.05.040

Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4

Rakesh Heer^*, Wei Shen Tan, Paul Gravestock, Thenmalar Vadiveloo, Rebecca Lewis, Steven Penegar, Luke Vale, Graeme MacLennan, Emma Hall, PHOTO Trial Team

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

The Platinum Opinion by Stenzl et al. [1] in European Urology, as well as the Words of Wisdom by de Angelis et al. [2], brings a welcome discussion on the role of photodynamic diagnosis (PDD)-guided transurethral resection of bladder tumour (TURBT) in non–muscle-invasive bladder cancer (NMIBC) on the basis of our recently published PHOTO trial [3]. The seminal finding from PHOTO was that at 3 yr, there was no difference in the rate of recurrence between PDD and white light (WL) resection groups. However, there are several points raised by Stenzl et al. [1] and de Angelis et al. [2] that require clarification.

Original language	English
Pages (from-to)	309-312
Number of pages	4
Journal	European Urology
Volume	85
Issue number	3
Early online date	15 Jun 2023
DOIs	https://doi.org/10.1016/j.eururo.2023.05.040
Publication status	Published - Mar 2024

Bibliographical note

Funding Information:
Funding/Support and role of the sponsor: PHOTO was sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust and coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research. Data management and statistical analyses were conducted by the Centre for Healthcare Randomised Trials at the University of Aberdeen. Cost-effectiveness analysis was conducted by the Health Economics Group at Newcastle University. This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and has been published in full in the Health Technology Assessment journal ( https://doi.org/10.3310/plpu1526 ). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Further project information is available on the NIHR Journals Library website ( https://www.journalslibrary.nihr.ac.uk/hta/#/ ).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2023.05.040Licence: Unspecified

Cite this

Heer, R., Tan, W. S., Gravestock, P., Vadiveloo, T., Lewis, R., Penegar, S., Vale, L., MacLennan, G., Hall, E., & PHOTO Trial Team (2024). Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4. European Urology, 85(3), 309-312. https://doi.org/10.1016/j.eururo.2023.05.040

Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4. / Heer, Rakesh; Tan, Wei Shen; Gravestock, Paul et al.
In: European Urology, Vol. 85, No. 3, 03.2024, p. 309-312.

Research output: Contribution to journal › Comment/debate › peer-review

Heer, R, Tan, WS, Gravestock, P, Vadiveloo, T, Lewis, R, Penegar, S, Vale, L, MacLennan, G, Hall, E & PHOTO Trial Team 2024, 'Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4', European Urology, vol. 85, no. 3, pp. 309-312. https://doi.org/10.1016/j.eururo.2023.05.040

@article{1e774e29e31d49ecb78696f82dcb391f,

title = "Reply to Arnulf Stenzl, Morgan Roupr{\^e}t, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4",

abstract = "The Platinum Opinion by Stenzl et al. [1] in European Urology, as well as the Words of Wisdom by de Angelis et al. [2], brings a welcome discussion on the role of photodynamic diagnosis (PDD)-guided transurethral resection of bladder tumour (TURBT) in non–muscle-invasive bladder cancer (NMIBC) on the basis of our recently published PHOTO trial [3]. The seminal finding from PHOTO was that at 3 yr, there was no difference in the rate of recurrence between PDD and white light (WL) resection groups. However, there are several points raised by Stenzl et al. [1] and de Angelis et al. [2] that require clarification.",

author = "Rakesh Heer and Tan, {Wei Shen} and Paul Gravestock and Thenmalar Vadiveloo and Rebecca Lewis and Steven Penegar and Luke Vale and Graeme MacLennan and Emma Hall and {PHOTO Trial Team}",

note = "Funding Information: Funding/Support and role of the sponsor: PHOTO was sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust and coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research. Data management and statistical analyses were conducted by the Centre for Healthcare Randomised Trials at the University of Aberdeen. Cost-effectiveness analysis was conducted by the Health Economics Group at Newcastle University. This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and has been published in full in the Health Technology Assessment journal ( https://doi.org/10.3310/plpu1526 ). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Further project information is available on the NIHR Journals Library website ( https://www.journalslibrary.nihr.ac.uk/hta/#/ ).",

year = "2024",

month = mar,

doi = "10.1016/j.eururo.2023.05.040",

language = "English",

volume = "85",

pages = "309--312",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

TY - JOUR

T1 - Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4

AU - Heer, Rakesh

AU - Tan, Wei Shen

AU - Gravestock, Paul

AU - Vadiveloo, Thenmalar

AU - Lewis, Rebecca

AU - Penegar, Steven

AU - Vale, Luke

AU - MacLennan, Graeme

AU - Hall, Emma

AU - PHOTO Trial Team

N1 - Funding Information: Funding/Support and role of the sponsor: PHOTO was sponsored by The Newcastle upon Tyne Hospitals NHS Foundation Trust and coordinated by the Clinical Trials and Statistics Unit at The Institute of Cancer Research. Data management and statistical analyses were conducted by the Centre for Healthcare Randomised Trials at the University of Aberdeen. Cost-effectiveness analysis was conducted by the Health Economics Group at Newcastle University. This project was funded by the National Institute for Health and Care Research (NIHR) Health Technology Assessment programme and has been published in full in the Health Technology Assessment journal ( https://doi.org/10.3310/plpu1526 ). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care. Further project information is available on the NIHR Journals Library website ( https://www.journalslibrary.nihr.ac.uk/hta/#/ ).

PY - 2024/3

Y1 - 2024/3

N2 - The Platinum Opinion by Stenzl et al. [1] in European Urology, as well as the Words of Wisdom by de Angelis et al. [2], brings a welcome discussion on the role of photodynamic diagnosis (PDD)-guided transurethral resection of bladder tumour (TURBT) in non–muscle-invasive bladder cancer (NMIBC) on the basis of our recently published PHOTO trial [3]. The seminal finding from PHOTO was that at 3 yr, there was no difference in the rate of recurrence between PDD and white light (WL) resection groups. However, there are several points raised by Stenzl et al. [1] and de Angelis et al. [2] that require clarification.

AB - The Platinum Opinion by Stenzl et al. [1] in European Urology, as well as the Words of Wisdom by de Angelis et al. [2], brings a welcome discussion on the role of photodynamic diagnosis (PDD)-guided transurethral resection of bladder tumour (TURBT) in non–muscle-invasive bladder cancer (NMIBC) on the basis of our recently published PHOTO trial [3]. The seminal finding from PHOTO was that at 3 yr, there was no difference in the rate of recurrence between PDD and white light (WL) resection groups. However, there are several points raised by Stenzl et al. [1] and de Angelis et al. [2] that require clarification.

UR - http://www.scopus.com/inward/record.url?scp=85163352573&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2023.05.040

DO - 10.1016/j.eururo.2023.05.040

M3 - Comment/debate

C2 - 37330372

AN - SCOPUS:85163352573

SN - 0302-2838

VL - 85

SP - 309

EP - 312

JO - European Urology

JF - European Urology

IS - 3

ER -

Reply to Arnulf Stenzl, Morgan Rouprêt, J. Alfred Witjes, Paolo Gontero. High-quality Transurethral Resection of Bladder Tumour Needs Additional Forms of Tumour Delineation. Eur Urol 2023;83:193–4

Abstract

Bibliographical note

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this